malaysiangKUALA LUMPUR, Dec 13 — Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company, has announced clinical data from an ongoing Phase 1 study (NCT04288726) of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) therapy being co-developed by Baylor College of Medicine and Tessa.
The results demonstrated a favourable safety profile and encouraging signs of efficacy with clinical responses observed in seven out of nine patients, including a complete disappearance of tumour reported in four patients.
According to a statement, the data was presented in an oral poster presentation at the 63rd Annual Meeting of the American Society of Hematology (ASH).
The ASH poster entitled, ‘Safety and efficacy of off-the-shelf CD30.CAR-modified Epstein-Barr virus-specific T cells in patients with CD30-positive lymphoma’, reported data from nine heavily pre-treated patients with advanced CD30-positive Hodgkin lymphoma who were administered TT11X across three dosing levels.
TT11X was well tolerated with no dose limiting toxicities observed, including no evidence of graft-versus-host disease (GVHD), neurotoxicity or a grade 3 or higher CRS (Cytokine release syndrome).
Clinical response was observed in seven patients spanning all three dose levels, including four complete responses and three partial responses, with an overall response rate of 77.8 per cent.
Partial responses were reported in three patients while disease progression occurred in two patients treated at low and mid-level doses. Longer term follow-up on durability of responses is currently ongoing.
“The expanded data presented at ASH builds on interim results from a smaller data set released earlier this year, and so far, our findings have been compelling,” stated Ivan Horak, M.D., Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics.
The four-day ASH Annual Meeting ends Dec 14. The poster can be viewed via the conference’s virtual platform.
Source: BERNAMA News Agency
